Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells.
The potential use of oncolytic viruses in the treatment of cancer has been investigated for some time. A variety of agents have been studied, including some which appear to be selectively replication-competent in cancer cell lines. In this study, we have investigated the ability of herpesvirus saimiri to specifically lyse selected human cancer cell lines. Upon infection with a replication-competent virus carrying the EGFP reporter gene and a neomycin resistance marker, the pancreatic cancer lines MIAPACA and PANC-1 exhibited definite cytopathic effects. In contrast, the colonic carcinoma cell lines SW480 and HCT116 were phenotypically unaltered. In addition, stable cell lines could not be generated from PANC-1 infected cultures, in marked contrast to cultures of cells from other human tissues. Virus recovery assays demonstrated that all of the cell lines produced a small amount of virus post-infection, but that virus replication was minimal after 1 week in culture. In addition, treatment with acyclovir inhibited virus replication but paradoxically increased cytopathic effect. These data suggest that herpesvirus saimiri may have potential as an oncolytic agent for the treatment of pancreatic cancer.
Molecular Medicine Unit, University of Leeds, St. James's University Hospital, UK.
A J
AJ
Stevenson
M S
MS
Giles
K T
KT
Hall
D J
DJ
Goodwin
M A
MA
Calderwood
A F
AF
Markham
A
A
Whitehouse
D015316:Genetic Therapy / Q000379:methods; D006566:Herpesviridae Infections / Q000821:virology; D006567:Herpesvirus 2, Saimiriine; D006801:Humans; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy* / Q000821:virology*; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000821:virology